A new drug class that offers cardioprotective properties are sodium-glucose co-transporter-2 (SGLT-2) inhibitors, initially used for the treatment of type 2 diabetes. Shortly after their introduction into the market they have been shown to have cardioprotective properties that are beyond the effect of lowering the glucose concentration in the blood. After further investigations their application in non-diabetic patients suffering from heart diseases has been approved. The underlying mechanisms of the observed effects, however, have not yet been identified. To get an impression of the influence of Cana-, Dapa- and Empagliflozin on cardiomyocytes, differentiated a human cardiomyocyte cell line (AC16) has been treated with the three Gliflozins in two different concentrations. Moreover, thermal profiling assays (TPP) and the use of activity-based probes (ABP) to identify interaction partners of the drugs are planned to be used in the project.